KT209
/ Kali Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 13, 2026
A NOVEL TRISPECIFIC ANTIBODY KT209 TARGETING CD19, CD20, AND CD3 (CD19XCD20XCD3) DEMONSTRATED POTENT ACTIVITY IN B-CELL DISEASES WITH LOWER CYTOKINE RELEASES
(EHA 2026)
- "Critically, it effectively lysed CD19-low or CD20-low variants more potent than Blinatumomab or Glofitamab. By simultaneously targeting two B-cell antigens, this approach may improve depth and duration of response. These data support the clinical development of KT209 for patients with broad relapsed/refractory B cell diseases."
Trispecific • Hematological Malignancies • Leukemia
1 to 1
Of
1
Go to page
1